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Abstract
The toxicity by 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) is thought to be caused by activation of the aryl hydrocarbon
receptor (AHR). However, our understanding of how AHR activation by TCDD leads to toxic effects is poor. Ideally we would
like to manipulate AHR activity in specific tissues and at specific times. One route to this is expressing dominant negative
AHRs (dnAHRs). This work describes the construction and characterization of dominant negative forms of the zebrafish Ahr2
in which the C-terminal transactivation domain was either removed, or replaced with the inhibitory domain from the
Drosophila engrailed repressor protein. One of these dnAhr2s was selected for expression from the ubiquitously active e2fa
promoter in transgenic zebrafish. We found that these transgenic zebrafish expressing dnAhr2 had reduced TCDD induction
of the Ahr2 target gene cyp1a, as measured by 7-ethoxyresorufin-O-deethylase activity. Furthermore, the cardiotoxicity
produced by TCDD, pericardial edema, heart malformation, and reduced blood flow, were all mitigated in the zebrafish
expressing the dnAhr2. These results provide in vivo proof-of-principle results demonstrating the effectiveness of dnAHRs in
manipulating AHR activity in vivo, and demonstrating that this approach can be a means for blocking TCDD toxicity.
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Introduction
The aryl hydrocarbon receptor (AHR) is the ligand-activated
subunit of a heterodimeric transcription factor found in numerous
vertebrate cell types [1]. Agonist binding at the AHR PAS B
domain triggers a conformational change that ultimately moves
the normally cytosolic receptor into the nucleus where it dimerizes
with its partner, the AHR nuclear translocator (ARNT). The
activated heterodimer binds to canonical DNA sequences known
as AHR Enhancers (AHREs) to drive transcription of target genes
[2].
The AHR is activated by a variety of ligands, including some
polycyclic aromatic hydrocarbons (PAHs), certain polychlorinated
biphenyls (PCBs), and a number of other compounds. Activation
of the AHR induces transcription of a core set of genes involved in
xenobiotic metabolism. These include genes encoding cytochrome
P450 1A (CYP1A), and UDP-glucuronosyltransferase (UDPGT)
involved in biotransformation. Because these enzymes degrade the
ligands that activate AHR, the system acts as an environmental
sensor that facilitates the detoxification of xenobiotics [3]. The
most potent AHR agonist known is 2,3,7,8 tetrachlorodibenzo-p-
dioxin (TCDD). TCDD is noteworthy in being poorly degraded
by the enzymes induced by AHR, and because it is lipophilic, this
stable AHR agonist has a long half-life in biological systems.
Due to genome duplication events, zebrafish have multiple Ahr
and Arnt isoforms, including three Ahrs (Ahr1a, Ahr1b, and Ahr2)
[4,5,6] and two Arnts (Arnt1 and Arnt2) with multiple splice
variants [6,7]. Previous work has shown that Ahr2 and Arnt1c are
responsible for TCDD toxicity in zebrafish; knocking down the
expression of either of these proteins blocks most if not all toxicity
[7,8].
The AHR protein can be divided into several domains (Fig. 1).
An N-terminal basic helix-loop-helix domain is responsible for
DNA binding. This is followed by two PAS domains, PAS A and
PAS B. PAS domains are named for the Per-Arnt-Sim superfamily
of proteins containing these domains, and are often associated with
small ligands that influence conformation and signalling
[9,10,11,12]. These N-terminal domains are highly conserved
between AHRs from different species. The C-terminal half of the
AHR is responsible for mediating transactivation. In general, the
C-terminus contains multiple transactivation domains (TADs) [13]
including a bipartite acidic domain [14], a glutamine rich domain
[13,15], and a proline/serine/threonine rich domain [13];
however, the presence and function of these domains can vary
among AHR orthologs [16,17] and paralogs [5].
Although AHR activation can serve a protective role, it is
known that inappropriate activation can induce a variety of toxic
responses, especially in early development. This has led many to
conclude that AHR also plays a role in controlling developmental
processes [3]; however, the nature of this role remains obscure.
Embryos are particularly sensitive to TCDD, and exposure during
defined developmental windows disrupts normal morphogenesis
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28020[18]. Zebrafish embryos exposed to TCDD within the first few
hours of fertilization exhibit multiple signs of toxicity. The most
prominent signs of toxicity involve malformation of the skeleton,
especially in the craniofacial region [19], and disruption of the
cardiovascular system [20,21]. Cardiovascular toxicity is charac-
terized by reduced cardiac output, aberrant heart development
resulting in a stretched string-like heart, pericardial and yolk sac
edema, and reduced peripheral blood flow.
The fact that AHR activation by TCDD leads to tissue- and
developmental-specific toxicity raises questions that can only be
resolved by manipulation of AHR activity at specific times in
specific tissues. The use of morpholino oligonucleotides (MOs) has
enabled controlled knockdown of specific AHR and ARNT
isoforms. However, MOs are limited in their ability to knock down
gene expression in a temporally- and spatially-defined manner.
More important, the MOs are generally injected into the newly
fertilized egg and are only effective during the first few days after
fertilization.
Work establishing the functions of specific AHR domains has
made it possible to produce mutant AHR proteins with controlled
function. For example, manipulation of the PAS-B domain can
produce a constitutively active AHR [22].
It is also possible to diminish AHR function by removing key
domains, specifically abolishing the TAD in the C-terminus.
Dominant negative AHRs (dnAHRs) have been constructed by
making C-terminal truncations of mouse and human AHRs,
although their use has so far been limited to transient expression in
cell culture assays [15,23,24]. A truncated human AHR, lacking
the Q-rich and P/S/T domains, but retaining the acidic domain,
has dnAHR activity [15]. Another dnAHR was engineered with a
leucine to alanine mutation at position 678 that compromised the
Q-rich TAD [15]. In the mouse, more severe truncations
removing both the Q-rich, and the acidic TADs have been
required to produce dnAHRs [24].
Expression of a dnAhr2 in zebrafish would allow manipulation
of the AHR pathway in vivo without the use of agonist or antagonist
chemicals. This would be effective beyond the narrow time limit of
morpholino activity. In principle, tissue-specific expression of a
dnAhr2 in zebrafish could be used to address key questions
regarding the molecular mechanisms underlying TCDD toxicity.
Here we report the construction of a dnAhr2 and proof-of
principle experiments using this to protect a transgenic zebrafish
line from TCDD. We find that transgenic expression of a dnAhr2
produces highly significant, albeit incomplete, protection from
several end points of TCDD toxicity.
Methods
Oligonucleotides
Oligonucleotides used for PCR were synthesized by Integrated
DNA Technologies (Coralville, IA). All primers are written in the 59
to 39 direction. BK Reverse Primer: ACA GGA AAC AGC TAT
GAC CTT G. Ahr2
1–440mycB rev: CTA TCG CGA CAA GTC
CTC TTC AGA AAT AAG CTT TTG CTC AGG ACT CGA
GATTTTCTGGCCTTTGCTCTG.Ahr2
1–494rev:CTACTC
GAG GAC GGC TGC CAG GTG TTC CC. Ahr2
1–547 rev, CTA
CTCGAG CTG CACAGAGTG TTCTCCCA.Ahr2
1–599mycB
rev: CTA TCG CGA CAA GTC CTC TTC AGA AAT AAG
CTT TTG CTC ATT CCT CGA GTC CAA CTC TGA TAG
ACC CTC. EngFXhoI: ATA CCG TCT ACC TCG AGA GCC.
EngRApaI: GGG CCC AAG CTT GAT CCC AGA GCA GAT.
mycEngR2 rev: GGG CCC CTA TCG CGA CAA GTC CTC
TTC AGA AAT GAG CTT TTG CTC GAA GCT TGA TCC
CAG AGC AGA. BglIIF: AGA TCT CCC GGG CTG CAG GAA
TTC GAT. BglIIR: AGA TCT CTA TCG CGA CAA GTC CTC
TTC.
Plasmid Construction
Truncated pBKCMV-Ahr2 Plasmids. The truncated forms
of Ahr2 were amplified with PfuTurbo polymerase (Stratagene, La
Jolla, CA) using the previously described pBKCMV-Ahr2 plasmid
[25]. The BK reverse primer was used as a forward primer, this
amplified a portion of the native 59 UTR with a BamHI site on the
59 end. Reverse primers are as indicated for each truncation
product. The primers for Ahr2
1–440 and Ahr2
1–599 added a 16
myc tag to the amplicon. Amplified products for Ahr2
1–440,
Ahr2
1–494, Ahr2
1–547 and Ahr2
1–599 were TA sub-cloned into the
pGEM-T Easy vector (Promega) and sequenced. Constructs were
digested out of pGEM with BamHI and NotI and inserted into
pBKCMV at these sites.
pBKCMV-Ahr2
Eng. For the construction of pBKCMV-
Ahr2
Eng the repressor domain of Engrailed was Pfu amplified
from the pks/En vector template using EngFXhoI and EngRApaI
primers. The amplified product was TA sub-cloned into pGEM-T
Easy vector and sequenced to make pGem Engrailed. pGem
Engrailed was digested with XhoI and ApaI and inserted into
Figure 1. Maps of mutant AHRs. The full length Ahr2 is shown at top, with domains indicated. The different constructs made and tested are
shown below.
doi:10.1371/journal.pone.0028020.g001
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A myc tag was added to this construct by Pfu amplifying the Ahr2-
Engrailed fusion with the BK reverse primer and mycEngR2 rev.
The resulting product was TA sub-cloned into pGEM-T Easy and
sequenced. The insert was then digested out with BamHI and
NotI and placed back into a pBKCMV vector to make the final
myc tagged pBKCMV-Ahr2
Eng plasmid.
Ef1-a Ahr2
1–440. The Ahr2
1–440 sequence was Pfu amplified
with the BglIIF and BglIIR primers using the pBKCMV-Ahr2
1–
440 vector as a template, which flanked the insert with BglII sites.
The amplified product was sub-cloned into pGEM-T Easy and
sequenced. The Ahr2
1–440 sequence was excised from pGEM-T
Easy using BglII and inserted into the pW1x/B Ef1-a construct (a
generous gift from Elwood Linney) at BglII. Orientation was
determined by restriction digest.
Ef1-a Ahr2
Eng. The Ahr2
Eng sequence was Pfu amplified with
the BglIIF and BglIIR primers using the pBKCMV-Ahr2
Eng
vector as a template, which flanked the insert with BglII sites. The
amplified product was sub-cloned into pGEM-T Easy and
sequenced. The Ahr2
Eng sequence was excised from pGEM-T
Easy using BglII and inserted into the pW1x/B Ef1-a construct at
BglII. Orientation was determined by restriction digest.
Transient Transactivation Assay
COS-7 cells were seeded on 24-well plates at a density of 5610
4
cells/well 1 day before transfection [5,26]. Transfections were
performed using SuperFect (QIAGEN). Each well was co-
transfected with 400 ml of serum-containing media containing
pBKCMV expression constructs for Ahr2 (225 ng) and Arnt2b
(450 ng). For dominant negative testing, Ahr2
1–440, Ahr2
1–499,
Ahr2
1–547, Ahr2
1–599 or Ahr2
Eng (225 ng each) were added to the
assay as indicated. When a dnAHR plasmid was not added, empty
vector was included so that in all assays the total amount of
plasmid - both expression plasmid and reporters remained
constant.
The pGudluc 1.1 reporter vector was obtained from Dr.
Michael Denison (University of California, Davis, CA). This
reporter vector is based on pGL2-Basic and has the firefly
luciferase gene under control of a 484-bp fragment of the mouse
CYP1A1 enhancer that contains 4 DREs and the murine
mammary tumor virus promoter [27]. The pGudluc luciferase
reporter construct (100 ng) was included in all transfections as
indicated, along with a b-galactosidase CMV reporter (100 ng) to
control for transfection efficiency.
Media was removed by vacuum aspiration, each well was
washed with 16PBS and 100 ml of passive lysis buffer was added.
Plates were incubated 20 min at room temperature on an orbital
shaker. Cell lysis was confirmed microscopically and 10-ml aliquots
were transferred to a 96-well luminometer plate. Luminescence
assays were completed using a Dynatech Laboratories ML-2250
luminometer (Chantilly, VA) as follows: 50 ml of luciferase assay
buffer II was injected into each well, incubated 2 s, and the
resulting luminescence integrated over the next 10 s.
Luciferase activity was normalized to b-galactosidase activity for
each sample [26]. Vector controls with no AHR or ARNT
expression produced no luciferase activity. Significance was
determined using a two-tailed Student’s t-test assuming unequal
variances.
Microinjection of Ahr2 Constructs
Fertilized eggs were obtained from adult AB strain zebrafish
bred in our laboratory as described by Westerfield (1995). Newly
fertilized eggs were injected with either Ahr2
1–440 or Ahr2
Eng at
the one- to two-cell stage with approximately 13 ng of linearized
plasmid. Zebrafish were grown to maturity at 27u, outcrossed to
wild type AB fish and the resulting embryos were collected for
PCR analysis to determine whether they produced transgenic
offspring [28].
All work was done in an ALAC-accredited facility with an
IACUC-approved animal care and use protocol # M489
approved by the University of Wisconsin School of Medicine
and Public Health (SMPH) Animal Care and Use Committee.
Moreover, much of the motivation for the work is based on an
interest in animals and this guided efforts to ameliorate any
suffering. In fact, all experimental work utilized embryos at very
early stages of development. While there is no way a human can
know how an animal feels, our best estimates indicate that
suffering is connected with complexity in behavioral repertoire.
These small embryos show few signs of distress and were often
terminally anesthetized in our experiments.
Waterborne TCDD Exposure of Zebrafish Embryos
TCDD of .99% purity obtained from Chemsyn (Lenexa, KS)
was dissolved in dimethyl sulfoxide and used to make a 1 mg/mL
TCDD stock solution. Embryos (2–4 hours post-fertilization) were
statically exposed to vehicle (0.1% dimethyl sulfoxide) or TCDD
(1.0 ng/ml) for 1-h in glass scintillation vials with gentle rocking as
described [29]. After the 1-h static exposure, embryos were rinsed
with clean water and maintained in vehicle/TCDD-free water for
the remainder of experiments.
Ethoxyresorufin O-deethylase Assay
An in vivo EROD assay was used to assess Cyp1A activity [30].
Embryos were exposed to 7-ethoxyresorufin (0.4 mg/ml, Sigma)
for 5 min and immobilized in 3% methylcellulose for epifluores-
cence microscopy (excitation l, 577 nm; emission l, 620 nm).
Western Blot
Embryos (20/sample, 72 hpf) obtained from transgenic lines or
from a wild type AB strain were euthanized with MS-222
(1.67 mg/ml, Sigma-Aldrich, St. Louis, MO), homogenized with a
microfuge tube pestle in 40 mLo f2 6SDS sample buffer, heated at
95u for 5 min, centrifuged at 13,000 g for 10 min, and the
supernatants were loaded onto an 8% SDS-polyacrylamide gel. As
a positive control, Ahr2
1–440 protein was translated in vitro using
the TNT T7/T3 Coupled System (L5040, Promega) and the myc
tagged pBKCMV-Ahr2
1–440 plasmid as the template. Proteins
were transferred to a nitrocellulose membrane, and probed using
an anti-myc antibody (MS-139-P0, Lab Vision Corporation,
Fremont, CA). Protein was visualized using the ECL Plus
detection kit (Amersham) followed by exposure to radiographic
film.
Toxicity Assessment
Embryos were obtained from Line 26 or the isogenic AB wild
type spawns just after fertilization. Exposures consisted of 20
embryos from each group placed in water and statically exposed to
TCDD (1 ng/ml, 2 ml) or vehicle for 1 h, rinsed with clean water,
and sorted into 96-well plates (1 embryo/well) [20,29]. Each
toxicity experiment was repeated 4 times. At 96 hpf the larva were
scored for severity of pericardial edema, defects in heart looping,
and reduced caudal blood flow. Pericardial edema was assessed
from a lateral view; heart looping was assessed from a ventral
viewpoint. For blood flow assessment larva were observed laterally
and the rate of flow as blood traversed from the caudal artery to
the caudal vein was scored. The scale used was: 0 - no defect; 1 -
defect difficult to detect; 2 - defect clearly present; 3 - defect
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two independent experiments. Significance was determined using
a two tailed Student’s t-test assuming unequal variances.
Assessments were performed using a Nikon Eclipse TE300
inverted microscope.
Results
Design and Construction of dnAhr2s
We hypothesized that loss of the TAD would produce an AHR
that could interact with ARNT and AHREs without yielding
transactivation, potentially competing at the protein and DNA
binding sites with endogenous AHR to produce a dominant
negative effect. The TAD is poorly conserved across species, and
work with mouse and human AHRs has demonstrated that
changes producing a dominant negative receptor in one AHR
isoform do not necessarily produce a dnAHR in another isoform.
As shown in Figure 1, our approach was to make progressive
deletions of the Ahr2 C-terminus. The smallest deletion removes
the Q-rich site, but keeps the acidic domain intact. Further
deletions bisect, and entirely remove the acidic domain. As an
alternative strategy, we attached the repressor domain from the
Drosophila melanogaster Engrailed protein to Ahr2
1–541 in an
attempt to actively repress transcription at Ahr2 target genes.
Some of the constructs were tagged with a myc epitope, allowing
western blotting with a commercially available monoclonal
antibody.
Ahr2
1–440 and Ahr2
Eng Act as dnAhr2s in Cell Culture
To test the mutant Ahr2s as dominant negatives, each construct
was co-transfected into a Cos7 cell assay system together with
expression plasmids encoding wild type Ahr2, and Arnt2b as well
as the pGudLuc1 luciferase reporter plasmid [27,31]. By
measuring luciferase activity in the presence of vehicle, or
10 nM TCDD, we could determine how each mutant Ahr2
affected normal Ahr2/Arnt2b transactivation (Fig. 2). As previ-
ously reported, the system produced luciferase activity even in the
DMSO control; however, TCDD further increased luciferase
activity [8,31].
The Ahr2
1–547 and Ahr2
1–599 constructs, retaining at least part
of the acidic domain, did not reduce reporter activity with TCDD
present, but did reduce the basal reporter activity in the absence of
TCDD. In contrast, Ahr2
1–440, Ahr2
1–494, and Ahr2
Eng inhibited
both constitutive luciferase activation, and activation following
TCDD exposure. Addition of the Engrailed domain converted
Ahr2
1–547, which did not antagonize Ahr2 activation on its own,
into a dnAhr2.
Construction and Validation of dnAhr2 Transgenics
We chose Ahr2
1–440, and Ahr2
Eng, the two strongest dnAhr2s,
to make transgenic zebrafish lines expressing the dnAhr2s from the
Xenopus laevis EF1-alpha promoter. PCR screening identified
putative germ-line positive founders, and these were further tested
using western blotting to confirm the presence of the epitope-
tagged protein in F1 embryos. Several putative Ahr2
Eng lines were
identified by PCR, but unfortunately none passed our western blot
screen for Ahr2
Eng protein expression. However, we found three
independent lines (15, 26 and 31) that express the Ahr2
1–440
transgene (Fig. 3). These produced a protein of the expected
molecular weight, matching the mobility of the protein expressed
in a cell-free lysate (TNT), and the band was not seen at all in
control extracts made from untagged wild type (WT) embryos. We
chose line 26 for further study.
Expression of Ahr2
1–440 Inhibits EROD Induction by TCDD
Activation of AHR by TCDD produces a massive induction of
cytochrome P4501a (Cyp1a) mRNA [32]. The Cyp1a oxidase
converts 7-ethoxyresorufin into the fluorescent product resorufin.
This allows AHR activity to be monitored in vivo by using
fluorescence microscopy [30] (Fig. 4). All zebrafish produce
Figure 2. In vitro transcription assays show dominant negative
activity. A Cos-7 cell transfection assay described in the Materials and
Methods was used to measure the ability of Ahr2 and ARNT to induce
luciferase reporter expression when different Ahr2 mutants were co-
expressed in the system. Light bars indicate activity in the absence of
TCDD; dark bars indicate activity in the presence of TCDD (1 ng/ml).
Units are Relative Luciferase Units, a dimensionless ratio of luciferase
activity from the luminometer divided by the b-galactosidase activity
from the control reporter used for transformation normalization [5,26].
Single asterisks: different from control no TCDD value, p,0.05. Double
asterisk significantly different from control +TCDD value, p,0.05.
doi:10.1371/journal.pone.0028020.g002
Figure 3. Western blot confirms expression of Ahr2
1–440 in
transgenic zebrafish lines. Embryos from the transgenic lines 15, 26
and 31, carrying the Ahr2
1–440 transgene were processed for western
blotting with an anti-myc antibody as described in Materials and
Methods. The lane carrying the mutant Ahr2
1–440 protein made in vitro
for use as a positive control is indicated as TNT, and a negative control
lane loaded with extract from wild type embryos having no myc tag is
indicated as WT.
doi:10.1371/journal.pone.0028020.g003
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in the control images; however, this is very slight when compared
to the intense fluorescence produced in wild type embryos exposed
to TCDD. This intense fluorescence is not observed in the absence
of the substrate (not shown). The TCDD-exposed embryos also
displayed hallmark signs of TCDD toxicity including pericardial
and yolk sac edema. In marked contrast, the transgenic zebrafish
expressing Ahr2
1–440 showed very little fluorescence in the
presence of TCDD. Exposure to vehicle alone produced no
fluorescence aside from autofluorescence normally seen in the yolk
and around the margins of the fish [32]. Thus, we detected no
evidence of Cyp1a in the absence of TCDD, while in the presence
of TCDD EROD activity was consistently and clearly reduced by
the presence of the Ahr2
1–440 transgene.
In Vivo Expression of Ahr2
1–440 Protects Against
Pericardial Edema
Pericardial and yolk sac edema are hallmark signs of TCDD
toxicity in early life stage fish. This edema formation is probably
secondary to heart failure induced by TCDD [20]. If the Ahr2
1–440
truly acts as a dnAHR, then it should protect the zebrafish embryos
from pericardial edema produced by TCDD. To test this, wild type
and dnAhr2
1–440 transgenic zebrafish embryos were exposed to
TCDD (1 ng/ml) for 1 hour immediately following fertilization.
Nearly 100% of the wild type embryos developed pericardial edema
by 72 hpf, and this became severe by 96 hpf. In contrast, several of
the offspring derived from the Ahr2
1–440 cross showed no
pericardial edema at all, and approximately 75% showed at least
partial protection (Fig. 5).
Ahr2
1–440 Protects against heart looping defects caused
by TCDD
Wild type zebrafish embryos exposed to TCDD initially form a
normal heart, with the atrium looping dorsally and to the left so
that it sits above the ventricle. However, by 72 hpf the hearts of
TCDD-exposed embryos begin to unloop, eventually forming a
linear, tube-like heart, such that the atrium sits behind, and in line
with the ventricle. In an experiment similar to that described
above, wild type and Ahr2
1–440 transgenic zebrafish were exposed
to TCDD and examined at 96 hpf. Nearly 80% of wild type
offspring exposed to TCDD displayed the expected severe defect
in heart looping, with an elongated, tube-like heart. In contrast,
almost 80% of dominant negative offspring were scored as having
only mild or moderate defects in heart looping (Fig. 6).
Approximately one quarter of the dnAhr2
1–440 offspring had
hearts that were still looped to the extent that the chambers
overlapped, lying adjacent to each other. This was never observed
in wild type embryos exposed to TCDD. These results show that
the dnAhr2
1–440 can reduce the cardiotoxicity of TCDD in
developing zebrafish.
Expression of dnAhr2
1–440 protects against reduced
blood flow
Reduced caudal blood flow is evident by 72 hpf in TCDD
exposed embryos [29,33]. By 96 hpf, caudal blood flow was
severely reduced or absent in 100% of wild type embryos exposed
to TCDD (Fig. 7). However, the dnAhr2
1–440 offspring were
protected against reduction in caudal blood flow, comparable to
Figure 4. InductionofCyp1abyTCDDisinhibitedindnAhr2
1–440-
transgenic zebrafish. Transgenic and wild type AB fish were exposed
to TCDD or vehicle and ethoxysresorufin was added as described in
Materials and Methods. Representative images showing the fluorescent
product of Cyp1a metabolism are shown for wild type AB and
dnAhr2
1–440 transgenic fish.
doi:10.1371/journal.pone.0028020.g004
Figure 5. dnAhr2
1–440 -transgenic zebrafish are resistant to
pericardial edema caused by TCDD. Transgenic and wild type AB
zebrafish were exposed to TCDD immediately following fertilization,
and the severity of pericardial edema was scored for each fish at 96 hpf.
For each type of fish, the bars indicate the distribution across each of
the 4 possible categories of severity: Dark bars indicate dnAhr2
1–440-
transgenics; light bars indicate wild type. Representative photographs
illustrate each severity score. Asterisk indicates a significant difference
between the transgenic and wild type percentage for that severity
category, p,0.05.
doi:10.1371/journal.pone.0028020.g005
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TCDD treatment halted blood flow in the wild type embryos,
blood flow continued in those embryos carrying the dnAhr2
1–440
transgene.
Discussion
AHR2 Structure Activity
Our in vitro assays for dnAhr2 activity allowed several
conclusions to be drawn regarding the zebrafish Ahr2. The most
obvious conclusion was that we needed to delete almost the entire
TAD in order to see a dominant negative effect in competition
assays with full-length Ahr2.
Because the Ahr2
1–547 and Ahr2
1–599 mutants had no dnAHR
activity, we initially concluded that they retained some normal
function. However, in direct transactivation assays comparing the
activities of different Ahr2 mutants cotransfected with ARNT, the
Ahr2
1–599 had only a small level of activity, despite retaining both
acidic domains (Fig. S1). The acidic domain of the zebrafish Ahr2
is therefore functional as a transactivation domain, but only
weakly so alone. Some other portion of the C-terminus is
responsible for most of the transactivation potential of Ahr2.
The Ahr2
1–547 and Ahr2
1–599 constructs did not inhibit TCDD
activated Ahr2; however, they did reduce basal activity. We can
only speculate about this since the basis for the commonly
observed high basal activity in the transfection assay has never
been identified. It is possible that in Cos7 cells, Ahr is expressed at
high enough levels to enter the nucleus unliganded and complex
with ARNT by mass action. Another possibility is that unidentified
AHR agonists are present in the cell culture system. Both models
suppose the presence of low levels of AHR/ARNT in the nucleus
without TCDD. The Ahr2
1–547 and Ahr2
1–599 constructs might
interfere with transactivation caused by low basal levels of Ahr2 in
the nucleus, but not be able to inhibit the higher Ahr2 levels
produced by TCDD.
In contrast to the results obtained with Ahr2
1–547 and Ahr2
1–599,
the co-expression of Ahr2
1–440, Ahr2
1–494, and Ahr2
Eng with Ahr2
inhibited both constitutive luciferase activation, and activation
following TCDD exposure. Addition of the Engrailed domain
strongly repressed luciferase induction and converted Ahr2
1–547,
which cannot antagonize Ahr2 activation on its own, into a strong
dominant negative receptor.
Mechanism of dnAhr2 Action
The COS7 cells were used because they have little if any
detectable endogenous AHR or ARNT activity. This makes a
good platform for adding different AHR and ARNT isoforms and
testing them with a luciferase reporter. While qualitatively useful,
the assay consistently has an unusually high basal response with no
TCDD added; TCDD addition then increases activity, but the
induction is only on the order of 2 fold. This is not an accurate
representation of the normal induction of the CYP1a1 promoter
by TCDD-activated AHR, in which basal activity is low, and fold
induction is high. The high COS-7 basal activity requires
expression of both AHR and ARNT [5,6,7,8,25,26,31,34].
The Ahr2
1–440 construct had a greater impact on basal than
TCDD-induced activity. Both were reduced; however if one
assumes that the TCDD-induced activity represents the sum of the
basal and added TCDD-induced activity, then it is possible that
the Ahr2
1–440 effect is due solely to a block of basal activity.
An alternative interpretation is that Ahr2
1–440 blocks both the
basal and the induced activity, but blocks the basal activity more
effectively; perhaps because the basal activity is, for reasons
unclear, weaker.
Although the COS-7 cell transfection assay has been widely
used, the source of the high basal activity remains obscure, and the
in vitro results do not distinguish between these possibilities.
However, the in vivo results clearly show reduced TCDD-induced
Cyp1a activity. This EROD activity is known to be dependent on
both AHR and Cyp1a. Furthermore, in the zebrafish embryo,
Figure 6. TCDD effects on heart morphology are reduced in
dnAhr2
1–440-transgenic zebrafish. Transgenic and wild type AB
zebrafish were exposed to TCDD immediately following fertilization,
and the severity of defects in heart looping and morphology were
scored for each fish at 96 hpf. For each type of fish, the bars indicate the
distribution across each of the 4 possible categories of severity: Dark
bars indicate dnAhr2
1–440-transgenics; light bars indicate wild type.
Representative sketches of heart morphology illustrate each severity
score. Asterisk indicates a significant difference between the transgenic
and wild type percentage for that severity category, p,0.05.
doi:10.1371/journal.pone.0028020.g006
Figure 7. TCDD-induced blood flow defects are reduced in
dnAhr2
1–440-transgenic zebrafish. Transgenic and wild type AB
zebrafish were exposed to TCDD immediately following fertilization,
and at 96 hpf caudal blood flow was scored for each fish. Scores were:
3, no flow; 2, clearly diminished flow; 1 slightly diminished flow; 0
normal flow. The bars indicate the distribution across each of the
severity categories: Dark bars indicate dnAhr2
1–440-transgenics; light
bars indicate wild type. Representative photographs illustrate each
edema severity score. Asterisk indicates a significant difference between
the transgenic and wild type percentage for that severity category,
p,0.05.
doi:10.1371/journal.pone.0028020.g007
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subtraction of basal activity could not account for the reduction in
TCDD-induced EROD activity observed in the strain carrying the
Ahr2
1–440 transgene. The Ahr2
1–440 transgene must have
impacted TCDD-induced AHR activity.
It is likely that further efforts to obtain the Ahr2
Eng transgenic
line would yield a strain with a stronger dnAHR effect; however,
our goal was to demonstrate that expression of an altered mutant
AHR could be used to block TCDD effects in a living organism.
The Ahr2
1–440 served this purpose.
A dominant negative could act by sequestering ARNT in a
complex unable to bind to AHREs, leaving no remaining ARNT
protein molecules for productive interactions with Ahr2. The
dnAhr2 might form a complex with ARNT that can bind AHREs
but cannot regulate transcription. Binding to ARNT is required
for both mechanisms. Deletion of the entire C-terminal half was
needed to produce dnAhr2 activity. This suggests that dominant
negative activity stems from the production of an intact DNA
binding and dimerization module, without any remaining TADs.
This idea is strengthened by our ability to create a dnAHR by
adding the engrailed repressor to the C-terminus.
dnAhr2 and TCDD Toxicity
The Ahr2
1–440 transgenic fish did not display any developmen-
tal abnormalities, which is consistent with previous reports where
Ahr2 was knocked down in zebrafish using morpholinos [8]. The
construction of Ahr (2/2) null mouse lines has indicated a
developmental role for the mouse AHR in a number of tissues
[35,36,37,38,39]. However, our results suggest that inhibition of
endogenous Ahr2 in our transgenic line was not total and therefore
we cannot address whether zebrafish Ahr2 has a role during
normal development, as low levels of active Ahr2 protein may be
sufficient to perform potential developmental functions. Regard-
less, we observed no effects of the transgene on untreated animals
and they grew and developed normally.
Fish from all 4 groups - line 26 and wild type; treated and
untreated - survived until the 96 hpf point to the same extent. This
is because the transgene by itself did not affect survival, and
TCDD-induced lethality does not occur until after 120 hpf.
Therefore, very similar numbers of individuals were scored in all 4
groups. Of the groups of 20 embryos chosen for each assay,
survival at 96 hpf ranged from 15–20, with no individual
treatment or strain consistently showing greater survival over the
4 independent experiments.
At 96 hpf the Ahr2
1–440 transgenic fish showed very obvious
protection against TCDD toxicity. However, the protection was
rarely complete. Furthermore, we were not able to bring any of the
Ahr2
1–440 transgenic fish to adulthood after TCDD exposure,
even though their appearance showed marked protection. This
may be due to the summation of partial toxicities. One point to
bear in mind is that the exposure to TCDD was at 1 ng/ml, while
exposure of the same duration at 100 pg/ml is sufficient to
produce 100% mortality. Survival to adulthood requires the
completion of numerous hurdles, and our dominant negative
protein may simply not be able to protect against all actions of
TCDD, nor completely block AHR hyperactivation.
The effects of the transgene were remarkably specific, being
observable only when the receptor target for the dnAHR was
activated by TCDD. We have used a variety of transgenic
zebrafish carrying both transgenic reporters and functional
proteins with this ef1-a plasmid and other vector backbones. None
of these have protected against TCDD toxicity. Therefore, the
effect cannot be ascribed to the vector.
The basis for dominant negative proteins first proposed by
Herskowitz [40] is that competition will occur between the normal
protein and the mutant protein for some key cellular component.
This competition mechanism ties the degree of effect of the
dominant negative to its level of expression, relative to the level of
the normal protein. With this in mind, the partial rescue of TCDD
toxicities is not surprising at all.
To be effective as a competitor, the dnAhr2 must be expressed
at levels sufficient to overwhelm the endogenous AHR2. It is not
clear whether the EF1-alpha promoter produces expression levels
that are sufficient to accomplish this in all tissues in vivo. Tissue
specific silencing of EF1-alpha has been reported [41].
Despite these shortcomings, our proof-of-principle experiments
clearly show the potential for manipulating the AHR pathway
using dnAHRs in transgenic animals. This opens the doorway to a
variety of whole animal experiments in which inducible, tissue-
specific promoters can be used to downregulate AHR signaling in
specific tissues at specific times. This extends our ability to study
AHR function, TCDD toxicity, and development in a whole
animal vertebrate system.
Supporting Information
Figure S1 In vitro transactivation assays show Ahr2
1–599
activity. The Cos-7 cell transactivation assay similar to that
described in Figure 2 was used to measure the transcriptional
activity of different Ahr2 mutants when paired with Arnt2b. Light
bars indicate activity in the absence of TCDD; dark bars indicate
activity in the presence of TCDD (1 ng/ml). Asterisks indicate
activity that is significantly higher than the control cells expressing
no Ahr or ARNT, p,0.05.
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